
RCEL Stock Forecast & Price Target
RCEL Analyst Ratings
Bulls say
AVITA Medical is a company with a positive outlook for the future due to recent developments such as securing a 10-year agreement with BARDA, an expanding wound care portfolio, and exiting its stabilization phase with a projected revenue growth of 12% to 19%. While the company's current focus is on the US region, it has potential for international growth in the future and is backed by strong government relationships and validation for its innovative burn treatment device. Some risk factors to consider are potential clinical/regulatory and financial risks, but the company's recent debt refinancing and progress in clinical trials provide confidence in its growth trajectory.
Bears say
AVITA Medical is currently dependent on government contracts to support the sales of their product, with minimal revenue coming from commercial sales. The company's single product, RECELL, has shown promising clinical results, but it remains to be seen if it can translate into sustained revenue growth beyond episodic government support. The recent updates and clinical data flow support the potential of Cohealyx as a complementary solution within AVITA's treatment ecosystem. However, the impact of reimbursement friction and high operating expenses have resulted in a significant net loss for the company. Until the company can demonstrate sustained revenue growth and improved financials, it is prudent to maintain a negative outlook on AVITA Medical's stock.
This aggregate rating is based on analysts' research of AVITA Medical Inc and is not a guaranteed prediction by Public.com or investment advice.
RCEL Analyst Forecast & Price Prediction
Start investing in RCEL
Order type
Buy in
Order amount
Est. shares
0 shares